These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7037980)
41. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Sterrett SP; Penniston KL; Wolf JS; Nakada SY Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229 [TBL] [Abstract][Full Text] [Related]
42. [On the diuretic and saluretic activity of p-hydroxytriamterene and methoxytriamterene (author's transl)]. Vollmer G; Mutschler E; Völger KD Arzneimittelforschung; 1981; 31(3):529-30. PubMed ID: 7194678 [TBL] [Abstract][Full Text] [Related]
43. Local factors compared with systemic factors in the formation of bladder uric acid stones. Li WM; Chou YH; Li CC; Liu CC; Huang SP; Wu WJ; Huang CH Urol Int; 2009; 82(1):48-52. PubMed ID: 19172097 [TBL] [Abstract][Full Text] [Related]
44. [Analytical evaluation of urinary calculi mineral composition]. Machoy P Ann Acad Med Stetin; 1995; 41():259-71. PubMed ID: 8615550 [TBL] [Abstract][Full Text] [Related]
45. Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. Cohen TD; Streem SB; Lammert G J Urol; 1996 Jan; 155(1):62-5. PubMed ID: 7490899 [TBL] [Abstract][Full Text] [Related]
46. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. McClennen W; Wilson T Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768 [TBL] [Abstract][Full Text] [Related]
47. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)]. Knauf H; Möhrke W; Mutschler E; Völger KD Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258 [TBL] [Abstract][Full Text] [Related]
48. Pattern of urinary tract stone diseases in Mekelle, Ethiopia. Alemu MH Ethiop Med J; 2008 Jul; 46(3):237-41. PubMed ID: 19271387 [TBL] [Abstract][Full Text] [Related]
49. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan? Verkoelen CF J Am Soc Nephrol; 2006 Jun; 17(6):1673-87. PubMed ID: 16707562 [TBL] [Abstract][Full Text] [Related]
50. [The most important factor for active urinary stone formation in patients with urolithiasis]. Simić-Ogrizović S; Dopsaj V; Jovicić S; Milenković D; Jovanović D; Nesić V Med Pregl; 2007; 60 Suppl 2():117-20. PubMed ID: 18928175 [TBL] [Abstract][Full Text] [Related]
51. Impact of stone location on success rates of endoscopic lithotripsy for nephrolithiasis. Perlmutter AE; Talug C; Tarry WF; Zaslau S; Mohseni H; Kandzari SJ Urology; 2008 Feb; 71(2):214-7. PubMed ID: 18308086 [TBL] [Abstract][Full Text] [Related]
52. Metabolic fate and solubility of triamterene--not an explanation for triamterene nephrolithiasis. Sörgel F; Ettinger B; Benet LZ J Pharm Sci; 1986 Feb; 75(2):129-32. PubMed ID: 3958920 [TBL] [Abstract][Full Text] [Related]
54. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)]. Knauf H; Mutschler E; Wais S; Wais U Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408 [TBL] [Abstract][Full Text] [Related]